CLAG-Based Induction Therapy in Previously Untreated High . . . CLAG-based therapy is a well-tolerated, efficacious induction strategy in previously-untreated patients with high risk AML CLAG-based regimens should be studied in a broader group of newly diagnosed AML patients
CLAG-M (Cladribine + Cytarabine + Filgrastim - ChemoExperts CLAG-M is typically given to patients with relapsed or refractory AML after one or more prior treatments The goal of CLAG-M is to eliminate leukemia cells from the body and to decrease symptoms from AML, such as bleeding, bruising, and recurrent infections
Clag (card game) - Wikipedia Clag is a trick-taking card game using a standard pack of 52 French-suited playing cards It is similar to oh hell , and can be played by three to seven players Clag originated in the Royal Air Force and started as an acronym for Clouds Low Aircraft Grounded
CLAG-M with dose-escalated mitoxantrone for adults with acute . . . Our study adds to the evidence supporting the use of CLAG-M for intensive AML re-induction therapy, perhaps particularly with higher mitoxantrone doses Perhaps more importantly, our study points to a role of this regimen in the upfront setting where it is currently not commonly used
CLAG-M Regimen Effective in Refractory Acute Myeloid Leukemia According to results recently published in the Annals of Hematology, the treatment regimen referred to CLAG-M appears highly effective in patients with acute myeloid leukemia (AML) that has stopped responding to standard therapies
Venetoclax plus CLAG-M for the Treatment of Relapsed or . . . This phase II trial compares the effect of venetoclax plus cladribine, cytarabine, filgrastim and mitoxantrone (CLAG-M) to CLAG-M alone in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed), or that has not responded to previous treatment (refractory)
CLAG±M (cladribine, cytarabine, granulocyte colony . . . Conclusions: CLAG±M resulted in high clinical responses and prolonged overall survival in pts with secondary and r r AML with poor risk features, specifically older age (³60 years old) and multiple prior lines of therapy including previous HMA
Venetoclax added to CLAG regimen might improve the outcome of . . . We aim to analyze the efficacy and safety of Venetoclax (Ven) added to cladribine + cytarabine + granulocyte colony-stimulating factor (G-CSF) ± idarubicin or mitoxantrone (CLAG ± Ida Mito) regimen as a salvage treatment of relapsed refractory acute